Sign in with
google
Pharmaceutical at 2019 cantor Healthcare conference
September 5, 2019
3.00pm
Welcome back
To keep connected with us please login with your personal info
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat
September 5, 2019
3.00pm
September 5, 2019
3.00pm
We focus on discovering and advancing new treatments for serious patient
needs. From the inception of a therapeutic through early clinical
development, our disease area teams collaborate across scientific
disciplines and organizations in support of our mission to improve and
extend peoples’ lives.
Our delivery platform is our research and development (R&D)
cornerstone — a robust and scalable engine for delivering therapeutic agents
that activate and direct immune responses in a controlled, impactful way.
Our R&D teams are able to leverage the unique mechanism of action of
our platform to impact the way we harness the immune system in the fight
against cancer and other serious diseases.
Maecenas at mi faucibus, accumsan ex et, gravida metus. Aliquam ullamcorper
imperdiet aliquam. Ut ut convallis libero, id pulvinar nisl. Cras Morbi neque
odio, cursus in ultricies vitae, eleifend sit amet odio. Aenean porta neque id
tincidunt congue. Praesent semper semper sollicitudin. Fusce at dictum nisi.
Maecenas commodo, justo ac sodales malesuada, velit urna viverra ante, molestie
aliquet nulla risus ut turpis. Donec iaculis.
Mauris luctus feugiat nibh, sed pharetra magna porta id. Etiam eu
velit volutpat, mollis risus non, dictum elit. Aenean nec facilisis orci.landit
nulla faucibus ornare. Class aptent taciti sociosqu ad litora torquent per
conubia nostra, per inceptos himenaeos. Phasellus sodales imperdiet neque semper
vel. Nunc urna lacus, sagittis eu nulla vel, sagittis placerat erat. Nulla
facilisi. Suspendisse lacus erat, laoreet placerat quis justo. Quisque bibendum
et magna vitae laoreet. Proin vehicula dictum arcu, eget semper ligula hendrerit
ut.
These cutting edge monotherapies typically provide lasting benefits to about 20 percent of patients, leaving a significant unmet need for the remaining 80 percent. How, then, do we safely and efficiently transfer the remarkable anti-cancer effects of these novel therapies across a wider range of cancers? How do we help more patients?
Donec sollicitudin nisi nec sollicitudin maximus. Nulla facilisi. Vivamus malesuada tristique erat, sed auctor lacus volutpat quis. Integer eleifend tempus, vel lobortis nibh semper. Ut sem nibh, malesuada ac velit ut, scelerisque dapibus ante. Aliquam quam felis, blandit sit amet purus ac, malesuada tortor. Pellentesque pharetra fringilla ligula, sit amet luctus ipsum sollicitudin quis. Proin iaculis, ante nec blandit dictum, dui tellus et faucibus elit nulla in ante. In molestie quis nibh nec feugiat. Integer ut auctor magna. Nulla feugiat, arcu quis fermentum ullamcorper, sem mi amet convallis ipsum velit nec risus. Ut ac rutrum arcu, tincidunt pretium elit. Suspendisse in neque urna. Class aptent taciti sociosqu ad litora conubia nostra, per inceptos himenaeos. Etiam pellentesque ex enim, at vulputate nisi rutrum ullamcorper. Mauris blandit sem non mauris dolor molestie.